Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis

Patients with HER2-positive breast cancer (HER2 + BC) develop central nervous system metastases twice as often as patients with luminal HER2-negative breast cancer. Leptomeningeal progression results in a drastically altered prognosis with limited therapeutic options. This phase II study was conduct...

Full description

Bibliographic Details

Published in:	Neuro-oncology (Charlottesville, Va.) Va.), 2023-02, Vol.25 (2), p.365-374
Main Authors:	Oberkampf, Florence, Gutierrez, Maya, Trabelsi Grati, Olfa, Le Rhun, Émilie, Trédan, Olivier, Turbiez, Isabelle, Kadi, Amir, Dubot, Coraline, Taillibert, Sophie, Vacher, Sophie, Bonneau, Claire
Format:	Article
Language:	English
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Female Humans Life Sciences Meningeal Carcinomatosis - drug therapy Meningeal Carcinomatosis - secondary Pediatric Neuro-Oncology Quality of Life Receptor, ErbB-2 Trastuzumab
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!